Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma

References

• Zhou W, Zhu WG. The changing face of HDAC inhibitor depsipeptide. Curr Cancer Drug Targets 2009; 9:91 - 100; PMID: 19200053; http://dx.doi.org/10.2174/156800909787314039
   PubMed Web of Science ®Google Scholar
• Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008; 122:1891 - 1900; PMID: 18074352; http://dx.doi.org/10.1002/ijc.23295
   PubMed Web of Science ®Google Scholar
• Bloemen JG, Venema K, van de Poll MC, Olde Damink SW, Buurman WA, Dejong CH. Short chain fatty acids exchange across the gut and liver in humans measured at surgery. Clin Nutr 2009; 28:657 - 661; PMID: 19523724; http://dx.doi.org/10.1016/j.clnu.2009.05.011
   PubMed Web of Science ®Google Scholar
• Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004; 23:21 - 29; PMID: 14712207; http://dx.doi.org/10.1038/sj.onc.1207020
   PubMed Web of Science ®Google Scholar
• Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95:6791 - 6796; PMID: 9618491; http://dx.doi.org/10.1073/pnas.95.12.6791
   PubMed Web of Science ®Google Scholar
• Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 2008; 68:9601 - 9607; PMID: 19047136; http://dx.doi.org/10.1158/0008-5472.CAN-07-5270
   PubMed Web of Science ®Google Scholar
• Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002; 2:139 - 148; PMID: 12204534; http://dx.doi.org/10.1016/S1535-6108(02)00095-8
   PubMed Web of Science ®Google Scholar
• Zhang CZ, Chen GG, Lai PB. Transcription factor ZBP-89 in cancer growth and apoptosis. Biochim Biophys Acta 2010; 1806:36 - 41; PMID: 20230874
   PubMed Web of Science ®Google Scholar
• Bai L, Merchant JL. ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol 2001; 21:4670 - 4683; PMID: 11416144; http://dx.doi.org/10.1128/MCB.21.14.4670-83.2001
   PubMed Web of Science ®Google Scholar
• Bai L, Yoon SO, King PD, Merchant JL. ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ 2004; 11:663 - 673; PMID: 14963412
   PubMed Web of Science ®Google Scholar
• Law GL, Itoh H, Law DJ, Mize GJ, Merchant JL, Morris DR. Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J Biol Chem 1998; 273:19955 - 19964; PMID: 9685330; http://dx.doi.org/10.1074/jbc.273.32.19955
   PubMed Web of Science ®Google Scholar
• Merchant JL, Iyer GR, Taylor BR, Kitchen JR, Mortensen ER, Wang Z, et al. ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol Cell Biol 1996; 16:6644 - 6653; PMID: 8943318
   PubMed Web of Science ®Google Scholar
• Bai L, Kao JY, Law DJ, Merchant JL. Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection. Gastroenterology 2006; 131:841 - 852; PMID: 16952553; http://dx.doi.org/10.1053/j.gastro.2006.06.014
   PubMed Web of Science ®Google Scholar
• Bai L, Merchant JL. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J Biol Chem 2000; 275:30725 - 30733; PMID: 10899165; http://dx.doi.org/10.1074/jbc.M004249200
   PubMed Web of Science ®Google Scholar
• Bai L, Merchant JL. ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate. Biochem Biophys Res Commun 2007; 359:817 - 821; PMID: 17560543; http://dx.doi.org/10.1016/j.bbrc.2007.05.197
   PubMed Web of Science ®Google Scholar
• Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137:609 - 622; PMID: 19450511; http://dx.doi.org/10.1016/j.cell.2009.04.050
   PubMed Web of Science ®Google Scholar
• Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009; 29:2243 - 2253; PMID: 19223463; http://dx.doi.org/10.1128/MCB.00959-08
   PubMed Web of Science ®Google Scholar
• Trinh DL, Elwi AN, Kim SW. Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosis. Oncotarget 2010; 1:396 - 404; PMID: 21311096
   PubMed Web of Science ®Google Scholar
• Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9:701 - 713; PMID: 19693097
   PubMed Web of Science ®Google Scholar
• Okada M, Tessier A, Bai L, Merchant JL. p53 mutants suppress ZBP-89 function. Anticancer Res 2006; 26:2023 - 2028; PMID: 16827139
   PubMed Web of Science ®Google Scholar
• Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol 2003; 162:1823 - 1829; PMID: 12759240; http://dx.doi.org/10.1016/S0002-9440(10)64317-9
   PubMed Web of Science ®Google Scholar
• Merchant JL, Bai L, Okada M. ZBP-89 mediates butyrate regulation of gene expression. J Nutr 2003; 133:2456 - 2460; PMID: 12840224
   PubMed Web of Science ®Google Scholar
• Chen GG, Chan UP, Bai LC, Fung KY, Tessier A, To AK, et al. ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest. Cancer Lett 2009; 283:52 - 58; PMID: 19362768; http://dx.doi.org/10.1016/j.canlet.2009.03.024
   PubMed Web of Science ®Google Scholar
• Arts J, King P, Marien A, Floren W, Belien A, Janssen L, et al. JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009; 15:6841 - 6851; PMID: 19861438; http://dx.doi.org/10.1158/1078-0432.CCR-09-0547
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107:600 - 608; PMID: 19459166; http://dx.doi.org/10.1002/jcb.22185
   PubMed Web of Science ®Google Scholar
• Cang S, Ma Y, Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009; 2:22; PMID: 19486511; http://dx.doi.org/10.1186/1756-8722-2-22
   PubMed Web of Science ®Google Scholar
• Zhou GS, Liu SD, Zhang ZS, Zhang MJ, Li X, Wang YD, et al. Intrasplenic heterotransplantation of in vitro cultured human fetal hepatic stem cells for treatment of acute liver injury in mice with severe combined immunodeficiency. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27:817 - 820; PMID: 17584646
   PubMedGoogle Scholar
• Dagtas AS, Edens RE, Gilbert KM. Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4+ T cells. Int Immunopharmacol 2009; 9:1289 - 1297; PMID: 19664724; http://dx.doi.org/10.1016/j.intimp.2009.07.012
   PubMed Web of Science ®Google Scholar
• Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223:116 - 126; PMID: 21125670; http://dx.doi.org/10.1002/path.2784
   PubMed Web of Science ®Google Scholar
• Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010; 1:405 - 422; PMID: 21311097
   PubMed Web of Science ®Google Scholar
• Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007; 26:2243 - 2254; PMID: 17401433; http://dx.doi.org/10.1038/sj.onc.1210295
   PubMed Web of Science ®Google Scholar
• Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010; 9:1847 - 1855; PMID: 20436301; http://dx.doi.org/10.4161/cc.9.9.11545
   PubMed Web of Science ®Google Scholar
• Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, et al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011; 10:1679 - 1689; PMID: 21508668; http://dx.doi.org/10.4161/cc.10.10.15642
   PubMed Web of Science ®Google Scholar
• Napoli M, Girardini JE, Piazza S, Del Sal G. Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget 2011; 2:654 - 656; PMID: 21926448
   PubMed Web of Science ®Google Scholar
• Catasus L, Gallardo A, Cuatrecasas M, Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009; 22:522 - 529; PMID: 19234438; http://dx.doi.org/10.1038/modpathol.2009.5
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Takeuchi A, Miyaishi O, Isobe K, de Crombrugghe B. Cloning and characterization of a transcription factor that binds to the proximal promoters of the two mouse type I collagen genes. J Biol Chem 1997; 272:4915 - 4923; PMID: 9030551; http://dx.doi.org/10.1074/jbc.272.8.4915
   PubMed Web of Science ®Google Scholar
• Inazuka M, Tahira T, Horiuchi T, Harashima S, Sawabe T, Kondo M, et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford) 2000; 39:262 - 266; PMID: 10788533; http://dx.doi.org/10.1093/rheumatology/39.3.262
   PubMed Web of Science ®Google Scholar
• Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363 - 373; PMID: 15837625; http://dx.doi.org/10.1016/j.ccr.2005.02.019
   PubMed Web of Science ®Google Scholar
• Schuster A, Schilling T, De Laurenzi V, Koch AF, Seitz S, Staib F, et al. DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010; 9:2629 - 2639; PMID: 20581467; http://dx.doi.org/10.4161/cc.9.13.12110
   PubMed Web of Science ®Google Scholar
• Bai L, Merchant JL. Transcription factor ZBP-89 is required for STAT1 constitutive expression. Nucleic Acids Res 2003; 31:7264 - 7270; PMID: 14654702; http://dx.doi.org/10.1093/nar/gkg929
   PubMed Web of Science ®Google Scholar
• Xiao J, Zhang Z, Chen GG, Zhang M, Ding Y, Fu J, et al. Nucleophosmin/B23 interacts with p21WAF1/CIP1 and contributes to its stability. Cell Cycle 2009; 8:889 - 895; PMID: 19221506; http://dx.doi.org/10.4161/cc.8.6.7898
   PubMed Web of Science ®Google Scholar